Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 1, 2008, Pages 31-38

  Bianchi, Cristina ^a   Penno, Giuseppe ^a   Malloggi, Lucia ^b   Barontini, Rossana ^a   Corfini, Marisa ^a   Giovannitti, Maria G ^a   Di Cianni, Graziano ^a   Del Prato, Stefano ^a   Miccoli, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

Metabolic syndrome; Non traditional cardiovascular risk factors; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; CREATININE; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM ALBUMIN; UNCLASSIFIED DRUG; URIC ACID;

AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; ITALY; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK; RISK ASSESSMENT; RISK FACTOR;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; URIC ACID;

EID: 37349068107     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.07.007     Document Type: Article

References (35)

1. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
2. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and Management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 17 (2005) 2735-2752
3. World Health Organization. Definition, diagnosis and classification of diabetes and its complications. Part 1. In: World Health Organization diagnosis and classification of diabetes mellitus. Geneva (Tech. Resp. Ser. No. 99.2); 1999.
4. Balkau B., and Charles M.A. Comment on the provisional report from WHO consultation: European Group for the Study of insulin Resistance (EGIR). Diabet Med 16 (1999) 442-443
5. National Institutes of Health. Third report on the National Cholesterol Education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Washington, DC: U.S. Govt. Printing Office (NIH publ. no. 01-3670); 2001.
6. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 17 (2005) 2735-2752
7. Bloomgarden Z.T. Perspectives in diabetes: American Association of Clinical Endocrinologist (AACE) consensus on the insulin resistance syndrome. 25-26 August 2002, Washington, DC. Diabetes Care 26 (2003) 933-939
8. Alberti K.G., Zimmet P., and Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
9. Bonora E., Targher G., Formentini G., Calcaterra F., Lombardi S., Marini F., et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 21 (2003) 52-58
10. Marchesini G., Forlani G., Cerrelli F., Manini R., Natale S., Baraldi L., et al. WHO and ATP III proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 21 (2004) 383-387
11. Costa L.A., Canani L.H., Lisboa H.R., Tres G.S., and Gross J.L. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type diabetes. Diabet Med 21 (2004) 252-255
12. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
13. Bruno G., Merletti F., Biggeri A., Bargero G., Ferrero S., Runzo C., et al. Casale Monferrato Study. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes. Diabetes Care 27 (2004) 2689-2694
14. Kahn B., Buse J., Ferrannini E., and Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal. Diabetes Care 28 (2005) 2289-2304
15. Boizel R., Benhamou P.Y., Lardy B., Laporte F., Foulon T., and Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 23 (2000) 1679-1685
16. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
17. Muntner P., He J., Chen J., Fonseca V., and Whelton P.K. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes and the metabolic syndrome: analysis of the third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14 (2004) 686-695
18. Miccoli R., Bianchi C., Odoguardi L., Penno G., Caricato F., Giovannitti M.G., et al. Prevalence of the metabolic syndrome among Italian adults using ATP III definition. Nutr Metab Cardiovasc Dis 15 4 (2005) 250-254
19. Athyros V.G., Bouloukos V.I., Pehlivanidis A.N., Papageorgiou A.A., Dionysopoulou S.G., Symeonidis A.N., et al., MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: The MetS-Greece Multicentre Study. Diabetes Obes Metab 7 (2005) 397-405
20. Nowson C.A., Worsley A., Margerison C., Jorna M.K., Godfrey S.J., and Booth A. Blood pressure change with weight loss is affected by diet type in men. Am J Clin Nutr 81 5 (2005) 983-989
21. Pelkman C.L., Fishell V.K., Maddox D.H., Pearson T.A., Mauger D.T., and Kris-Etherton P.M. Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women. Am J Clin Nutr 79 2 (2004) 204-212
22. Didangelos T.P., Thanopoulou A.K., Bousboulas S.H., Sambanis C.L., Athyros V.G., Spanou E.A., et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type e DIAbetes (ORLICARDIA) study. Curr Med Res Opin 20 (2004) 1393-1401
23. Haffner S.M. Dyslipidemia management in adults with diabetes. (Technical Review). Diabetes Care 27 Suppl. 1 (2004) S68-S71
24. Saito I., Folsom A.R., Brancati F.L., Duncan B.B., Chambless L.E., and McGovern P.G. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 133 (2000) 81-91
25. Groop L., Ekstrand A., Forsblom C., Widen E., Groop P.H., Teppo A.M., et al. Insulin resistance, hypertension and microalbuminuria in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36 (1993) 642-647
26. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., Robbins D.C., Gabriel M., and Haffner S.M. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes 47 (1998) 793-800
27. Karalliedde J., and Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 17 10 (2004) 986-993
28. Niskanen L.K., Laaksonen D.E., Nyyssonen K., Alfthan G., Lakka H.M., Lakka T.A., et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164 14 (2004) 1546-1551
29. Danesh J., Lewington S., and Thompson S.G. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular disease and nonvascular mortality: an individual participant meta-analysis. JAMA 294 14 (2005) 1799-1809
30. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary Prevention Study. Circulation 108 (2003) 414-419
31. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEPT-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants aged 50 years and older. Diabetes 52 (2003) 1210-1214
32. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death cardiovascular events, and hospitalization. N Engl J Med 351 13 (2004) 1296-1305
33. Lu W., Resnick H.E., Jablonski K.A., Jones K.L., Jain A.K., Howard W.J., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. The Strong Heart Study. Diabetes Care 26 (2003) 16-23
34. Verlato G., Muggeo M., Bonora E., Corbellini M., Bressan F., and de Marco R. Attending the diabetes center is associated with increased 5-year survival probability of diabetic patients: the Verona Diabetes Study. Diabetes Care 19 3 (1996) 211-213
35. DAI Study Group. The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study. Diabet Med 21 7 (2004) 738-745